Walgreens Boots Alliance (WBA) Shows Resilience in Q2 with $37.1 B in Sales
Walgreens Boots Alliance demonstrated resilience and adaptability in its fiscal Q2, with a 6.3 percent increase in sales.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
In the latest quarterly financial disclosure, Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported a significant quarter amidst challenging retail landscapes, showing resilience and adaptability. The company achieved a 6.3 percent increase in sales, reaching $37.1 billion.
This growth, reflecting a 5.7 percent increase on a constant currency basis, was driven by sales enhancements across all segments, underscoring the diverse strength of WBA’s operations. However, the financial landscape was not without its challenges. The company faced a $13.2 billion operating loss, primarily due to a substantial $12.4 billion non-cash impairment charge related to VillageMD goodwill.
This stark contrast to the previous year’s operating income of $197 million underlines the volatile market conditions impacting the healthcare and retail sectors. Despite these hurdles, adjusted operating income stood at $900 million, a 26.5 percent decrease on a constant currency basis. This was partly due to lower sale-leaseback gains and softer U.S. retail performance, partially offset by an uptick in U.S. Healthcare segment profitability.
WBA Outperforms EPS Expectations with $1.20 Adjusted EPS
When juxtaposed with pre-set expectations, WBA’s performance presents a mixed bag. Analysts had projected earnings per share (EPS) of $0.82 and revenue of $35.9 billion for the quarter. WBA outperformed revenue expectations with its $37.1 billion in sales, indicating robust growth and operational success.
However, the adjusted EPS of $1.20, a 3.4 percent increase that surpasses expectations, is overshadowed by the substantial non-cash impairment charges, leading to a net loss of $5.9 billion for the quarter. This stark discrepancy underscores WBA’s challenges amid its growth trajectory and strategic realignments.
WBA Narrows Fiscal 2024 Adj. EPS Guidance to $3.20 to $3.35
Looking ahead, WBA narrows its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting the ongoing challenges in the U.S. retail environment and strategic portfolio adjustments.
This revised guidance stems from the early wind-down of the sale-leaseback program and lower earnings from share sales of its equity method investee, Cencora, counterbalanced by effective execution in pharmacy services and a favorable adjusted effective tax rate.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
